| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXO GRP LTD | Inhalation device |
Feb, 2016
(8 years ago) | |
|
US5873360 (Pediatric) | GLAXO GRP LTD | Inhalation device |
Aug, 2016
(7 years ago) | |
Advair Diskus 100/50 is owned by Glaxo Grp Ltd.
Advair Diskus 100/50 contains Fluticasone Propionate; Salmeterol Xinafoate.
Advair Diskus 100/50 has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Advair Diskus 100/50 are:
- US5873360
- US5873360*PED
Advair Diskus 100/50 was authorised for market use on 24 August, 2000.
Advair Diskus 100/50 is available in powder;inhalation dosage forms.
The generics of Advair Diskus 100/50 are possible to be released after 20 December, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-84) | Mar 31, 2012 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 24 August, 2000
Treatment: NA
Dosage: POWDER;INHALATION
More Information on Dosage
ADVAIR DISKUS 100/50 family patents
